Back to search
A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Data up to Jan 2025
Published2005
Citations19
References0
Total Citations Per Year
Abstract
References (0)
No references found
Cited By (0)
No citing papers found in database